FDMT vs KEYS · rev $37.0K vs P/E 57, rev $4.98B
4D Molecular Therapeutics Inc (FDMT) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
FDMT currently screens at market cap $518.1M. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.
Not investment advice. Open the FDMT and KEYS stock pages for the full models.
Not investment advice.